Raymond James Financial Inc. Purchases New Shares in Amedisys, Inc. (NASDAQ:AMED)

Raymond James Financial Inc. acquired a new position in shares of Amedisys, Inc. (NASDAQ:AMED) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 2,372 shares of the health services provider’s stock, valued at approximately $215,000.

A number of other hedge funds have also recently bought and sold shares of the company. National Bank of Canada FI lifted its position in shares of Amedisys by 119.0% during the third quarter. National Bank of Canada FI now owns 55,592 shares of the health services provider’s stock valued at $5,365,000 after purchasing an additional 30,213 shares in the last quarter. ABC Arbitrage SA purchased a new stake in Amedisys in the 4th quarter valued at about $2,522,000. Geode Capital Management LLC lifted its position in shares of Amedisys by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 567,105 shares of the health services provider’s stock worth $54,746,000 after buying an additional 7,071 shares in the last quarter. Oddo BHF Asset Management Sas purchased a new position in shares of Amedisys in the 3rd quarter worth approximately $7,238,000. Finally, Empowered Funds LLC purchased a new position in shares of Amedisys in the 4th quarter worth approximately $318,000. 94.36% of the stock is owned by hedge funds and other institutional investors.

Amedisys Stock Up 0.0 %

AMED opened at $91.51 on Friday. Amedisys, Inc. has a twelve month low of $82.15 and a twelve month high of $98.95. The company’s 50-day moving average price is $92.20 and its two-hundred day moving average price is $92.05. The stock has a market cap of $3.00 billion, a price-to-earnings ratio of 36.31, a PEG ratio of 1.78 and a beta of 0.89. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings results on Wednesday, February 26th. The health services provider reported $0.96 EPS for the quarter, missing analysts’ consensus estimates of $1.05 by ($0.09). Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The company had revenue of $598.05 million during the quarter, compared to the consensus estimate of $602.38 million. As a group, equities analysts expect that Amedisys, Inc. will post 4.4 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Stephens reissued an “equal weight” rating and issued a $101.00 price objective on shares of Amedisys in a research report on Tuesday, March 4th. Four analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $101.00.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.